Los Angeles Capital Management
TGTX icon

Los Angeles Capital Management’s TG Therapeutics TGTX Stock Holding History

Los Angeles Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$589K Sell
10,728
-13,643
-56% -$558K ﹤0.01% 865
2026
Q1 		$810K Buy
24,371
+7,301
+43% +$218K ﹤0.01% 735
2025
Q4 		$581K Hold
17,070
– – ﹤0.01% 832
2025
Q3 		$617K Buy
17,070
+1,956
+13% +$64.4K ﹤0.01% 854
2025
Q2 		$544K Buy
15,114
+6,497
+75% +$242K ﹤0.01% 837
2025
Q1 		$340K Sell
8,617
-64,500
-88% -$2.17M ﹤0.01% 855
2024
Q4 		$2.2M Sell
73,117
-50,284
-41% -$1.44M 0.01% 433
2024
Q3 		$2.89M Buy
123,401
+31,124
+34% +$680K 0.01% 393
2024
Q2 		$1.64M Buy
92,277
+15,661
+20% +$250K 0.01% 497
2024
Q1 		$1.17M Buy
76,616
+27,437
+56% +$437K ﹤0.01% 647
2023
Q4 		$840K Hold
49,179
– – ﹤0.01% 730
2023
Q3 		$411K Sell
49,179
-2,032
-4% -$28.3K ﹤0.01% 877
2023
Q2 		$1.27M Sell
51,211
-10,046
-16% -$259K 0.01% 596
2023
Q1 		$921K Sell
61,257
-98,053
-62% -$1.49M ﹤0.01% 697
2022
Q4 		$1.88M Sell
159,310
-3,905
-2% -$28.3K 0.01% 529
2022
Q3 		$966K Buy
163,215
+36,509
+29% +$239K 0.01% 710
2022
Q2 		$539K Buy
126,706
+116,446
+1,135% +$727K ﹤0.01% 940
2022
Q1 		$98K Buy
+10,260
New +$119K ﹤0.01% 1389
2021
Q3 		– Sell
-7,505
Closed -$291K – 1592
2021
Q2 		$291K Sell
7,505
-4,545
-38% -$178K ﹤0.01% 1400
2021
Q1 		$581K Buy
+12,050
New +$579K ﹤0.01% 1154
2020
Q3 		– Sell
-11,598
Closed -$226K – 1525
2020
Q2 		$226K Buy
+11,598
New +$187K ﹤0.01% 1365

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Los Angeles Capital Management's TGTX Position: Q2 2026 in Review

Los Angeles Capital Management reduced its TG Therapeutics (TGTX) stake by 56% in Q2 2026, selling an estimated $558K and leaving 10,728 shares worth $589K. The position accounts for ﹤0.01% of the portfolio, ranked #865.

Los Angeles Capital Management first reported a position in TGTX in Q2 2020 and has held it in 21 quarters since. The position peaked at $2.89M in Q3 2024. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Los Angeles Capital Management held 10,728 shares of TG Therapeutics worth $589K as of Q2 2026.
  • Los Angeles Capital Management sold 13,643 TG Therapeutics shares in Q2 2026, an estimated $558K.
  • TG Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #865 holding.
  • Los Angeles Capital Management first reported a position in TG Therapeutics in Q2 2020 and has held it in 21 quarters since.
  • Los Angeles Capital Management's TG Therapeutics position peaked at $2.89M in Q3 2024.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.